epicriptine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| ergot alkaloid derivatives | 4148 | 88660-47-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
a sec-butyl group replaces the isobutyl group of dihydroergocryptine
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
None
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Senile dementia | indication | 15662003 | |
| Alzheimer's disease | indication | 26929004 | DOID:10652 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.64 | acidic |
| pKa2 | 13.28 | acidic |
| pKa3 | 13.84 | acidic |
| pKa4 | 7.56 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 65914-79-6 | SECONDARY_CAS_RN |
| C3714499 | UMLSCUI |
| CHEBI:135927 | CHEBI |
| CHEMBL2106411 | ChEMBL_ID |
| DB11275 | DRUGBANK_ID |
| C527876 | MESH_SUPPLEMENTAL_RECORD_UI |
| 6220 | INN_ID |
| 5M64643B5U | UNII |
| 65667 | PUBCHEM_CID |
| 1426905 | RXNORM |
| 425819004 | SNOMEDCT_US |
| 75561002 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Ergoloid Mesylates | HUMAN PRESCRIPTION DRUG LABEL | 4 | 53489-281 | TABLET | 0.11 mg | ORAL | ANDA | 11 sections |
| Ergoloid Mesylates | HUMAN PRESCRIPTION DRUG LABEL | 4 | 68151-2780 | TABLET | 0.11 mg | ORAL | ANDA | 10 sections |